Research Article
Differences in Clinical and Imaging Features between Asymptomatic and Symptomatic COVID-19 Patients
Table 2
Pulmonary lobes involved by lesions [n (%)].
| | Classification | No of lobes involved | | | | 1–2 | 3–4 | 5 |
| | Early stage | | | | | 8.12 | 0.01 | | Asymptomatic (n = 19) | 14 (73.68) | 2 (10.53) | 3 (15.79) | | | | COVID-19 (n = 15) | 4 (26.67) | 7 (46.67) | 4 (26.67) | | |
| | Progression and peak stages | | | | | 3.28 | 0.19 | | Asymptomatic (n = 19) | 8 (42.11) | 3 (15.79) | 8 (42.11) | | | | COVID-19 (n = 27) | 8 (29.63) | 11 (40.74) | 8 (29.63) | | |
| | Early improvement stage | | | | | 1.18 | 0.55 | | Asymptomatic (n = 19) | 8 (42.11) | 5 (26.32) | 6 (31.58) | | | | COVID-19 (n = 27) | 8 (29.63) | 11 (40.74) | 8 (29.63) | | |
| | Late improvement stage | | | | | 0.71 | 0.74 | | Asymptomatic (n = 12) | 5 (41.67) | 3 (25.0) | 4 (33.33) | | | | COVID-19 (n = 23) | 8 (34.78) | 9 (39.13) | 6 (26.09) | | |
|
|
Note. Asymptomatic, those who remained asymptomatic; COVID-19, symptomatic COVID-19 patients.
|
